Genenta Science S.p.A. (GNTA) Stock Analysis
DELISTED
What happened to Genenta Science S.p.A. (GNTA) stock?
Genenta Science S.p.A. (GNTA) no longer trades on public markets. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
Market cap $18.0M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Genenta Science S.p.A. (GNTA). Genenta Science S.p.A. is an Italian clinical-stage biotechnology company focused on developing hematopoietic stem cell gene therapies for solid tumors. Its lead product candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation for glioblastoma multiforme.
Last analyzed: Jun 14, 2026Genenta Science S.p.A. (GNTA) Industrial Operations Profile
Genenta Science S.p.A. ADR Information Sponsored
Genenta Science S.p.A. (GNTA) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 2
- ADR Ratio: 1:1
More about this archive record
Can I still buy GNTA shares?
No. GNTA stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for GNTA elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before GNTA stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Genenta Science S.p.A.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.